Jenscare

Jenscare is a highly representative innovative medical device enterprise in the field of structural heart disease in China. Its self-developed transcatheter tricuspid valve replacement system (LuX-Valve) is currently the only product approved for registration clinical trials in China and is expected to be approved for marketing around 2023. In addition, Jenscare has established a technical reserve for innovative medical devices covering the field of structural heart disease, among which the aortic valve has entered formal clinical trials, and products such as the mitral valve have entered preclinical research.